Selhání léčby první linie a nesnášenlivost linie druhé aneb co dál, když oba dostupné inhibitory tyrosinkinázy 2. generace selhávají

Title in English First-line treatment failure and second-line intolerance or what to do if both available 2nd generation tyrosine kinase inhibitors fail


Year of publication 2020
Type Chapter of a book
MU Faculty or unit

Faculty of Medicine

Description Hematology is one of the traditional components of internal medicine. However, especially the development of hematooncology in recent decades has made hematology a very complex and demanding field with a major societal impact. In addition, hematology and hematooncology are evolving extremely rapidly. This concerns both the changes in the classification of a number of nosological units and, in particular, the rapid introduction of new substances into hematooncological treatment. Advances in diagnosis, and especially targeted and biological treatment, bring new hope to many patients. However, these new therapeutic options are not always fully exploited in practice.

You are running an old browser version. We recommend updating your browser to its latest version.

More info